Patients with impaired decision making capacity may participate in the study if a legal authorized representative is available to consent
Patients or their legal representatives must be able to read, understand, provide and sign informed consent to participate in the trial
Able to understand and sign an informed consent (or have a legal representative who is able to do so)
Able to provide informed consent, or have a legal representative able and willing to do so
Provide written informed consent (Subject or legal representative)
Subject or legal representative has ability to read, understand and provide written informed consent for study related procedures
Patients or their legal representative must be able to provide written informed consent;
Informed consent cannot be obtained either from the patient or legal representative
Patients or their legal representative must be able to read, understand and sign an informed consent
Adult patients must be able to understand and sign a written informed consent. For pediatric patients, the parent/legal guardian or representative must be able to understand and sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
Patients must be able to understand and be willing to give informed consent; parent or legal representative will be asked to consent for patients younger than 18 years old
Patients or their legal representative must be able to read, understand, and sign a written informed consent
Ability to understand and the willingness to sign a written informed consent document; patients with impaired decision making capacity may be eligible if they have a Legal Authorized representative or caretaker available
Patient or patient’s legal representative must provide written informed consent
Patient or patient’s legal representative able to sign informed consent
Provide written informed consent (or legal representative)
Written informed consent from patient or legal representative
Patient, or the patient’s legal representative, has voluntarily agreed to participate by giving written informed consent
Patient or patient’s legal representative able to provide written informed consent
Either the subject or the subject’s legal representative must be willing and able to provide written informed consent for the trial
Patient or patient’s legal representative, parent(s), or guardian able to provide written informed consent
Patient or patient’s legal representative, parent(s) or guardian able to provide written informed consent
Patient or patient’s legal representative, parent(s) or guardian able to sign informed consent; patients aged 7 to < 18 to provide assent
Patient (if ? 18 years old), or patient's legal representative(s) must have signed informed consent
Patients must be able to give informed consent; parent or legal representative will be asked to consent for patients younger than 18 year old
Subjects or their legal representative must be able to understand and provide written informed consent
All patients or their legal representative (for patients < 18 years old) must sign an Institutional Review Board (IRB) approved informed consent document (cGVHD natural history protocol 04-C-0281 or any National Cancer Institute [NCI] protocol allowing for screening procedures) prior to performing studies to determine patient eligibility; after confirmation of patient eligibility all patients or their legal representative must sign the protocol specific informed consent; for pediatric patients age appropriate assent will be obtained in accordance with NIH guidelines
Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Patients or their legal representative (if the patient is < 18 years old) must be able to read, understand and provide written informed consent to participate in the trial.
Signed, written informed consent by subject or legal representative prior to any trial-specific screening procedure
Subject or an authorized legal representative is willing and able to give prior written informed consent for investigation participation;
Patient or patient’s legal representative able to provide written informed consent
Patient or patient’s legal representative, parent(s) or guardian able to sign informed consent; age 7-18 able to provide assent
Written informed consent obtained from the patient/legal representative;
Written informed consent obtained from the patient/legal representative
Patient or patient’s legal representative, parent(s) or guardian able to sign informed consent
Patient or patient’s legal representative, parent(s) or guardian able to sign informed consent
Able to understand and sign an informed consent (or have a legal representative who is able to do so)
Patient or patient’s legal representative, able to sign informed consent
Patient or patient’s legal representative, parent(s) or guardian able to provide written informed consent for the long-term follow-up gene therapy study 2006-0676
Patients or their legal representative must be able to read, understand and sign an informed consent form (ICF)
Patients or their legal representatives must be able to read, understand, and provide informed consent to participate in the trial
Willingness to sign informed consent by patient or patient’s legal representative
Willing and able to understand and provide written informed consent. For minors or those incapable of providing written informed consent (i.e., incapacitated), understood, written and informed consent must be provided by a parent or legal guardian or representative.
Written patient or parental (or appropriate legal representative) IRB approved informed consent as appropriate.
Subjects, or subject's legal representative, who have provided signed informed consent, and assent when applicable, prior to participation.
Patients or their legal representative must be able to read (or have read to them), understand, and sign a written informed consent (approved by the institutional review board) within 14 days prior to start of treatment.
Patient (or legal representative) is able to understand and provide signed informed consent
Able to understand and sign an informed consent (or have a legal representative who is able to do so)
Written informed consent obtained from subject or subject’s legal representative and ability for subject to comply with requirements of the study
Patient or patient’s legal representative(s) is/are able to provide written informed consent to participate
Patient or legal representative must consent to multi-bio-frequency impedance analysis (MFBIA); the details are to be covered in consent
Adult patients must be able to understand and sign a written informed consent. For minor patients, the parent/legal guardian or representative must be able to understand and sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.
Patient or parent/legal guardian or representative lacks the full mental capacity to understand and sign a written informed consent.
Written informed consent in accordance with institutional and FDA (food and drug administration) guidelines must be obtained from all subjects (or patients' legal representative).
Able and willing (or have legal representative) to understand the study and provide consent
Subject/legal representative willing and able to provide written informed consent
has the ability to read, understand and provide written informed consent for the initiation of any study related procedures (or legal representative)
Informed consent cannot be obtained either from the patient or legal representative
Subject or his or her legal representative has the ability to read, understand and provide written informed consent for the initiation of any study related procedures
Written informed consent obtained prior any study-specific procedure (patient or parent(s) or legal representative)